Glenmede Trust’s NewAmsterdam Pharma NAMS Stock Holding History

Glenmede Trust’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$692K	Buy	20,420 +1,845	+10%	+$60.8K	﹤0.01%	880
2026 Q1	$595K	Sell	18,575 -3,640	-16%	-$119K	﹤0.01%	898
2025 Q4	$779K	Buy	+22,215	New	+$808K	﹤0.01%	798
2025 Q1	–	Sell	-9,965	Closed	-$256K	–	1421
2024 Q4	$256K	Sell	9,965 -17,455	-64%	-$371K	﹤0.01%	1158
2024 Q3	$455K	Buy	27,420 +290	+1%	+$5.02K	﹤0.01%	965
2024 Q2	$521K	Buy	27,130 +14,465	+114%	+$290K	﹤0.01%	890
2024 Q1	$300K	Buy	+12,665	New	+$257K	﹤0.01%	1063

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Glenmede Trust's NAMS Position: Q2 2026 in Review

Glenmede Trust increased its NewAmsterdam Pharma (NAMS) stake by 9.9% in Q2 2026, buying an estimated $60.8K and bringing the position to 20,420 shares worth $692K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

Glenmede Trust first reported a position in NAMS in Q1 2024 and has held it in 7 quarters since. The position peaked at $779K in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Glenmede Trust held 20,420 shares of NewAmsterdam Pharma worth $692K as of Q2 2026.
Glenmede Trust bought 1,845 NewAmsterdam Pharma shares in Q2 2026, an estimated $60.8K.
NewAmsterdam Pharma made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #880 holding.
Glenmede Trust first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 7 quarters since.
Glenmede Trust's NewAmsterdam Pharma position peaked at $779K in Q4 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.